Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 3

Acute migraine: Current treatment and emerging therapies

Authors Arun A Kalra, Debra Elliott

Published 15 July 2007 Volume 2007:3(3) Pages 449—459

Arun A Kalra, Debra Elliott

Department of Neurology, LSU Health Sciences Center, Shreveport, LA, USA

Abstract: Migraine is a common disabling primary headache disorder. Despite the need for a perfect treatment of this debilitating condition, the ideal “cure” eludes us. In 1992, the first triptan was released in the US for use in acute migraine. Triptans are more specific for the serotonin receptor 5-hydroxy triptamine (5-HT) 1 than previously prescribed drugs, such as ergotamines, with fewer side effects. This was an important first step in specific acute migraine therapy. Today however, triptans continue to be underutilized. There remains a concern, among practitioners and patients, about possible cardiovascular safety issues, despite the lack of strong evidence of serious adverse events. In fact, triptans now have a safe track record over more than a decade of use. Other perceived downfalls to use, include cost and variable efficacy. The more we learn about the clinical features and pathophysiology of migraine, the closer we are to finding a satisfactory monotherapy. Until then, recognizing that mixed mechanisms underlie migraine symptoms, rational polytherapy can be useful. Research on the roles of serotonin, calcitonin gene related peptide, glutamine and N-methyl-D-aspartate in the trigeminovascular system holds promise for those searching for the perfect migraine headache cure.

Keywords: migraine, pathophysiology, acute, treatment

Download Article [PDF] 

Readers of this article also read:

Matched control study of visual outcomes after arteriovenous sheathotomy for branch retinal vein occlusion

Yamane S, Kamei M, Sakimoto S, Inoue M, Arakawa A, Suzuki M, Matsumura N, Kadonosono K

Clinical Ophthalmology 2014, 8:471-476

Published Date: 26 February 2014

Ultraviolet damage to the eye revisited: eye-sun protection factor (E-SPF®), a new ultraviolet protection label for eyewear

Behar-Cohen F, Baillet G, de Ayguavives T, Ortega García P, Krutmann J , Peña-García P, Reme C, Wolffsohn JS

Clinical Ophthalmology 2014, 8:87-104

Published Date: 19 December 2013

Resveratrol in prevention and treatment of common clinical conditions of aging

M Andrea Markus, Brian J Morris

Clinical Interventions in Aging 2008, 3:331-339

Published Date: 6 June 2008

Review of tenofovir-emtricitabine

Saba Woldemichael Masho, Cun-Lin Wang, Daniel E Nixon

Therapeutics and Clinical Risk Management 2007, 3:1097-1104

Published Date: 15 January 2008

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma

Gennaro D’Amato, Antonello Salzillo. Amedeo Piccolo, Maria D’Amato, Gennaro Liccardi

Therapeutics and Clinical Risk Management 2007, 3:613-619

Published Date: 15 September 2007

Creating diagnostic scores using data-adaptive regression: An application to prediction of 30-day mortality among stroke victims in a rural hospital in India

Merrill D Birkner, SP Kalantri, Vaishali Solao, Priya Badam, Rajnish Joshi, Ashish Goel, Madhukar Pai, Alan E Hubbard

Therapeutics and Clinical Risk Management 2007, 3:475-484

Published Date: 15 July 2007

Editorial || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:211-212

Published Date: 15 May 2007

Oral mucositis induced by anticancer treatments: physiopathology and treatments

D’Hondt, Lionel, Lonchay, Christophe, André, Marc, Canon, Jean-Luc

Therapeutics and Clinical Risk Management 2006, 2:159-168

Published Date: 15 June 2006